semaglutide a1c reduction Change in HbA1c from baseline overall and in the dose Real-World Hemoglobin A1c Changes, Prescribing

Current evidence does not support prescribing GLP-1 receptor agonists solely for Parkinsons disease outside research settings

He says GLP-1s are approved for someone who's considered obese -- that's a BMI of 30 or more -- or overweight, if they have an underlying condition such as diabetes

Injectable GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda) mimic the glucagon-like peptide-1 hormone naturally released after eating

Thyroid hormone levels can also plummet with major weight loss, which can also slow follicle activity

I always say to patients who are scared of fillers, bad work is the work you see